|
Mar 21
|
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
|
|
Mar 21
|
Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?
|
|
Mar 20
|
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
|
|
Sep 4
|
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Jul 25
|
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
|
|
Mar 27
|
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
|
|
Mar 25
|
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
|
|
Dec 18
|
Plus Updates Financial and Cash Guidance for 2024
|
|
Nov 29
|
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
|
|
Nov 13
|
Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?
|
|
Nov 3
|
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
|
|
Aug 11
|
Positive Results Unveiled for Targeted CNS Cancer Treatment in Recent Study by Plus Therapeutics
|
|
Aug 11
|
EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer
|
|
Aug 11
|
Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference
|
|
Aug 8
|
Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023
|
|
Aug 8
|
Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference
|